Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase III Study of ME2080 (stiripentol) in Patients with Dravet Syndrome
jRCT2080221082Phase 3
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of stiripentol in Dravet syndrome, sponsored by Meiji Seika Pharma Co., Ltd.
02
Drugs
stiripentol
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on jRCT2080221082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221082.